Bronstein, Gewirtz & Grossman, LLC Is Investigating Replimune Group, Inc. (REPL) And Encourages Stockholders to Connect

NEW YORK CITY, NY / ACCESS Newswire / April 16, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group, Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL.

Replimune Investigation Details

On April 10, 2026, Replimune issued a press release announcing that it "received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Company's Biologics License Application (BLA) for RP1 in combination with nivolumab for the treatment of advanced melanoma." The Company indicated that there was disagreement between it and the FDA about the sufficiency of the data set used to support the application. Following this news, Replimune's stock price dropped $3.06 per share, or 64.29%, to close at $1.70 on April 13, 2026.

What's Next for Replimune Investors?

If you are aware of any facts relating to this investigation or purchased Replimune securities, you can assist this investigation by visiting the firm's site: bgandg.com/REPL. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Replimune Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Replimune Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC

View the original press release on ACCESS Newswire

COMTEX_477365016/2457/2026-04-16T11:01:25